- Current report filing (8-K)
April 20 2011 - 4:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
April 20, 2011
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its
charter)
|
|
|
|
|
DELAWARE
|
|
0-19731
|
|
94-3047598
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
333 LAKESIDE DRIVE, FOSTER CITY,
CALIFORNIA
(Address of principal executive offices)
94404
(Zip Code)
(650) 574-3000
(Registrants telephone number, including area code)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
SECTION 2 FINANCIAL INFORMATION
Item 2.02 Results of Operations and Financial Condition.
On April 20, 2011, Gilead Sciences, Inc., a Delaware corporation (Gilead), issued a press release announcing its financial results
for the quarter ended March 31, 2011. A copy of the press release is filed as Exhibit 99.1 to this report.
Gilead has
presented certain financial information in accordance with GAAP and also on a non-GAAP basis for the first quarter of 2011 and 2010. Management believes this non-GAAP information is useful for investors, taken in conjunction with Gileads GAAP
financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to
supplement an understanding of Gileads operating results as reported under U.S. GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7 and 10 of the press release filed as Exhibit 99.1 to
this report.
The information in this Form 8-K and the exhibit attached hereto shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
SECTION 9 FINANCIAL
STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and
Exhibits.
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press Release, issued by Gilead Sciences, Inc. on April 20, 2011
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
|
GILEAD SCIENCES, INC.
|
(Registrant)
|
|
/s/ Robin L. Washington
|
Robin L. Washington
Senior Vice President and Chief Financial Officer
|
Date:
April 20, 2011
Exhibit Index
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press Release, issued by Gilead Sciences, Inc. on April 20, 2011
|
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024